An insight into future antibacterial therapy

Emerging Microbes and Infections

Volumn 1, Issue , 2012, Pages

  Cozzone, Alain J ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIBIOTIC AGENT; AX 20017; LED 209; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL CELL; BACTERIAL VIRULENCE; CHEMICAL MODIFICATION; CHROMOSOME MUTATION; DRUG RESEARCH; DRUG TARGETING; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NOTE; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; STREPTOCOCCUS PNEUMONIAE; X RAY CRYSTALLOGRAPHY;

EID: 84878357278     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2012.35     Document Type: Note

References (30)

1. Jabes D. The antibiotic R & D pipeline: an update. Curr Opin Microbiol 2011; 14: 564-569.
2. Schultz C, Geerlings S. Plasmid-mediated resistance in Enterobacteriaceae: changing landscape and implications for therapy. Drugs 2012; 72: 1-16.
3. Martinez M, Silley P. Antimicrobial drug resistance. Handb Exp Pharmacol 2010; 199: 227-264.
4. Zhang Y, Heym B, Allen B et al. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992; 358: 591-593.
5. Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, causes resistance to antituberculous drug pyrazinamide in tubercle Bacillus. Nature Medicine 1996; 2: 662-667. (Pubitemid 26191953)
6. Goodwin A, Kersulyte D, Sisson G et al. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol Microbiol 1998; 28: 383-393. (Pubitemid 28182260)
7. Theuretzbacher U. Resistance drives antibacterial drug development. Curr Opin Pharmacol 2011; 11: 433-438.
8. Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nature Rev Microbiol 2010; 8: 423-435.
9. Fischbach MA. Combination therapies for combating antimicrobial resistance. Curr Opin Microbiol 2011; 14: 519-523.
10. Roemer T, Davies J, Giaever G et al. Bugs, drugs and chemical genomics. Nat Chem Biol 2011; 8: 46-56.
11. Bassetti M, Ginocchio F, Mikulska M et al. Will new antimicrobials overcome resistance among Gramnegatives? Expert Rev Anti Infect Ther 2011; 9: 909-922.
12. Ma Q, Yu Z, Han B et al. [Research progress in fusion expression of antimicrobial peptides.] Sheng Wu Gong Cheng Xue Bao 2011; 27: 1408-1416. Chinese.
13. Pucci MJ. Novel genetic techniques and approaches in the microbial genomics era: identification and/or validation of targets for the discovery of new antibacterial agents. Drugs RD 2007; 8: 201-212. (Pubitemid 47026338)
14. Manai M, Cozzone, AJ. Analysis of the protein kinase activity of Escherichia coli cells. Biochem Biophys Res Commun 1979; 91: 819-826. (Pubitemid 10145354)
15. Wang JH, Koshland DE Jr. Evidence for protein kinase activities in the prokaryote Salmonella typhimurium. J Biol Chem 1978; 253: 7605-7608.
16. Pereira SFF, Goss L, Dworkin J. Eukaryote-like serine/threonine kinases and phosphatases in bacteria. Microbiol Molec Bio Rev 2011; 75: 192-212.
17. Grangeasse C, Cozzone AJ, Deutscher J et al. Tyrosine phosphorylation: an emerging device of bacterial physiology. Trends Biochem Sci 2007; 32: 86-94. (Pubitemid 46199194)
18. Mijakovic I, Macek B. Impact of phosphoproteomics on studies of bacterial physiology. FEMS Microbiol Rev 2012; 36: 877-892.
19. Lengeler JW, Jahreis K. Bacterial PEP-dependent carbohydrate: phosphotransferase systems couple sensing and global control mechanisms. Contrib Microbiol 2009; 16: 65-87.
20. Goulian M. Two-component signaling circuit structure and properties. Curr Opin Microbiol 2010; 13: 184-189.
21. Ge R, Shan W. Bacterial phosphoproteomic analysis reveals the correlation between protein phosphorylation and bacterial pathogenicity. Genom Proteom Bioinform 2011; 9: 119-127.
22. Scherr N, Honnappa S, Kunz G et al. Structural basis for the specific inhibition of protein kinase G, a virulence factor of Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2007; 104: 12151-12156. (Pubitemid 47185645)
23. Grangeasse C, Nessler S, Morera S et al. Inhibitors of bacterial tyrosine kinase and uses thereof. World Intellectual Property Organization. WO/2009/133209A1, 2009
24. Stephenson K, Hoch JA. Two-component and phos-phorelay signal-transduction systems as therapeutic targets. Curr Opin Pharmacol 2002; 2: 507-512.
25. Rasko DA, Moreira CG, Li DR et al. Targeting QseC signaling and virulence for antibiotic development. Science 2008; 321: 1078-1080.
26. Li N, Wang F, Niu S et al. Discovery of novel inhibitors of Streptococcus pneumoniae based on the virtual screening with the homology-modeled structure of histidine kinase VicK. BMC Microbiol 2009; 9: 129-139.
27. Debarbouillé M, Dramsi S, Dussurget O et al. Characterization of a serine/threonine kinase involved in virulence of Staphylococcus aureus. J Bacteriol 2009; 191: 4070-4081.
28. Olivares-Illana V, Meyer P, Bechet E et al. Structural basis for the regulation mechanism of the tyrosine kinase CapB from Staphylococcus aureus. PLoS Biol 2008; 6: e143.
29. Lee DC, Zheng J, She YM et al. Structure of Escherichia coli tyrosine kinase Etk reveals a novel activation mechanism. EMBO J 2008; 27: 1758-1766.
30. Bechet E, Gruszczyk J, Terreux R et al. Identification of structural and molecular determinants of the tyrosine kinase Wzc and implications in capsular polysaccharide export. Molec Microbiol 2010; 77: 1315-1325.